Q & A With Dr. Sunil Verma: Targeted Treatments for HER2-Positive Breast Cancer

Anna Azvolinsky, PhD
Published Online: April 29, 2014
Sunil Verma, MD, MSEd, FRCPC

Sunil Verma, MD, MSEd, FRCPC

In the last decade, there have been tremendous improvements in the treatment of HER2-positive breast cancer with new HER2-targeted agents improving survival in both the adjuvant and metastatic settings. At the Miami Breast Cancer Conference, we spoke about this progress and the current focus of research in the HER2-positive breast cancer setting with breast cancer expert, Sunil Verma, MD, MSEd, FRCPC, an associate professor at the University of Toronto and chair of Breast Medical Oncology at the Sunnybrook Odette Cancer Centre in Toronto, Canada.

What is the current state of HER2-targeted therapy in metastatic disease?

Verma: In metastatic disease, over the past decade, we have seen a nearly doubling of the overall survival (OS) for patients with metastatic HER2-positive breast cancer since the pivotal publication of Slamon et al, in 2001, which showed an improvement from a 20-month to 25-month survival with integration of trastuzumab, and now we are seeing an improvement in OS with the addition of pertuzumab with docetaxel in the CLEOPATRA study, which is beyond 45 months. This survival improvement has been fueled through integration of new agents, such as pertuzumab, and also through the continuation of HER2-positive therapy with trastuzumab and lapatinib. The other key achievement is the development of T-DM1. This is the first time in solid tumors that an antibody-drug conjugate has been shown to be associated with an improvement in OS with superior toxicity profile. And so having both an improved OS with less toxicity is a remarkable achievement for our patients with HER2-positive disease.

Related Articles
Prudence Francis, MD, discusses the SOFT trial, which examined suppression of ovarian function, and the impact it could have on the future treatment of women under 35 with HR+ breast cancer.
Acting two months ahead of its deadline, the FDA granted an accelerated approval to palbociclib (Ibrance) as a first-line treatment for patients with ER-positive metastatic breast cancer.
Metastatic disease accounts for the vast majority of cancer-related deaths. Ensuring a definitive diagnosis and the most effective treatment in a timely fashion is essential for extending life expectancy.
Joan Lunden discusses the diagnostic approach that led to the early detection of triple-negative breast cancer, which was undetected by mammogram and 3D mammogram but was detected with ultrasound.
JTT Articles
Immune Checkpoint Inhibitors for Renal Cell Carcinoma
Mutant-Specific Epidermal Growth Factor Receptor Inhibitors
From the Editor: PARP Inhibitors, Biomarker Research, and Gene Editing
External Resources

MJH Associates
AJMC
Cure
HCPLive
OncLive
Pharmacy Times
Specialty Pharmacy Times
Physicians' Education Resource
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2015
Intellisphere, LLC. All Rights Reserved.